# Idera Pharmaceuticals

Source: https://onco.cc/companies/idera-pharmaceuticals/  
OnCo record `idera-pharmaceuticals` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Idera was a Cambridge biotech whose injected TLR9 agonist tilsotolimod, given into tumours with ipilimumab, failed a phase 3 trial in anti-PD-1-refractory melanoma in 2021.

## Summary

Idera Pharmaceuticals, founded in 1989 and based in Cambridge, Massachusetts, developed oligonucleotide Toll-like receptor agonists. Its intratumoural TLR9 agonist tilsotolimod was tested with ipilimumab in the phase 3 ILLUMINATE-301 trial in melanoma that had progressed on anti-PD-1 therapy and did not improve response or survival. The company merged with Aceragen in 2022 and later wound down. Its trials remain on ClinicalTrials.gov under Idera as lead sponsor.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Idera Pharmaceuticals, Inc.; Idera; Aceragen
- Tags: ctgov-sponsor
- HQ: Cambridge, MA
- Type: biotech
- Website: http://www.iderapharma.com

## Sources

- Official website: http://www.iderapharma.com
- ClinicalTrials.gov: trials led by Idera Pharmaceuticals, Inc.: https://clinicaltrials.gov/search?lead=Idera%20Pharmaceuticals%2C%20Inc.
- Wikidata: https://www.wikidata.org/wiki/Q30296240

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/)
- technologies: [In situ vaccination](https://onco.cc/technologies/in-situ-vaccination/)
- terms: [Clinical trial](https://onco.cc/terms/clinical-trial/), [Pivotal (registrational) trial](https://onco.cc/terms/pivotal-trial/)

---
JSON: https://onco.cc/api/v1/entities/idera-pharmaceuticals.json